文献速递神经核医学肿瘤 PET/CT

18F-FDG PET用于痴呆评估:共病病理、新疾病及抗淀粉样蛋白治疗时代的作用

18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in the Era of Antiamyloid Treatment.
PubMed 文献 · Semin Nucl Med · 2025-05-29

本文综述脑18F-FDG PET作为成熟影像生物标志物在痴呆评估中的作用,涵盖其在理解痴呆性疾病机制、提高临床诊断准确性、识别共病病理、认识新疾病、治疗规划及疗效评估中的应用,并讨论抗淀粉样蛋白治疗获批后体内生物标志物的加速应用。

要点

  • 脑FDG PET是成熟的影像生物标志物,用于研究脑代谢并辅助痴呆的临床诊断与治疗规划。
  • 抗淀粉样蛋白治疗已开发并获批用于阿尔茨海默病,加速了体内生物标志物在研究、临床试验和临床实践中的应用。
  • FDG PET有助于识别共病病理、认识新疾病、制定治疗方案及评估疗效。

核心结论

  • 脑FDG PET是研究脑代谢的成熟影像生物标志物,在痴呆的临床与研究场景中具有价值,尤其适用于痴呆治疗相关评估。

研究设计与样本

  • 本文为综述,围绕脑FDG PET在痴呆评估中的作用进行文献总结。

主要发现

  • 多种生物标志物(包括18F-FDG PET)的发展有助于理解痴呆性疾病的机制并推动研究与临床进展。
  • FDG PET的应用带来更准确的临床诊断、共病病理的识别、对新疾病的理解、治疗规划及疗效评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dementia, which impairs a person's cognition and ability in daily tasks and is often caused by neurodegenerative disorders, remains one of the most challenging neuropsychiatric conditions. The prevalence of dementia has been steadily increasing in aging societies. Recently, antiamyloid treatment has been developed and approved for the treatment of Alzheimer's disease (AD), which is known as the major cause of dementia. Such therapeutic developments have accelerated the use of in vivo biomarkers in research, clinical trials, and clinical practice. Past and recent developments of several biomarkers, including 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), have played a pivotal role in understanding the underlying mechanisms of dementing disorders and accelerating progress in both research and clinical practice, leading to more accurate clinical diagnosis, recognition of co-pathologies, better understanding of new diseases, treatment planning, and response evaluation. This article reviews the roles of brain FDG PET, one of the well-established imaging biomarkers, as a valuable tool for studying brain metabolism and its applications in clinical and research settings, particularly for the treatment of dementia.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thientunyakit T, Muangpaisan W, Minoshima S, et al. 18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in the Era of Antiamyloid Treatment. Semin Nucl Med. 2025. PMID: 40447541. doi:10.1053/j.semnuclmed.2025.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。